This year's S&P 500 leader sinks: Moderna suffers on Wall Street as melanoma vaccine data leaks.
Its shares fell as much as 25% after the data was circulated on social media. The drug company had gained more than 700% in the year before this fall. Its revaluation tripled the rise of tech companies like Micron.